Premium Nahrungsergänzungsmittel | artgerecht

Difucosyllactose Mixture – HMOs in Breast Milk

The difucosyllactose mixture is a group of human milk oligosaccharides naturally found in breast milk that act as prebiotics, supporting infant gut development and immune maturation.

Regular tips about health Regular tips about health

Things worth knowing about "Difucosyllactose Mixture"

The difucosyllactose mixture is a group of human milk oligosaccharides naturally found in breast milk that act as prebiotics, supporting infant gut development and immune maturation.

What Is a Difucosyllactose Mixture?

The difucosyllactose mixture refers to a blend of structurally related human milk oligosaccharides (HMOs) belonging to the group of fucosylated lactose derivatives. These compounds consist of the milk sugar lactose with two fucose units attached. Depending on the position and type of glycosidic bond, different isomers are formed, collectively referred to as the difucosyllactose mixture. These oligosaccharides occur naturally in human breast milk and are part of the complex HMO fraction considered essential for healthy infant development.

Biological Functions

The components of the difucosyllactose mixture serve several important roles in the infant body:

Prebiotic effect: These oligosaccharides are not digested in the infant small intestine and reach the colon intact, where they serve as a nutrient source for beneficial bacteria such as Bifidobacterium species, promoting the growth of a healthy gut microbiome.
Immune modulation: HMOs such as difucosyllactoses influence the neonatal immune system by supporting the maturation of immune cells and regulating inflammatory processes.
Protection against pathogens: Due to their structure, difucosyllactoses can act as decoy receptors, binding pathogens and toxins and thereby preventing their attachment to the gut mucosa.
Support of brain development: Fucose-containing HMOs have been associated with neuronal development and cognitive maturation in infants.

Occurrence and Sources

Difucosyllactose compounds are found primarily in human breast milk. The concentration and composition of HMOs vary individually and depend, among other factors, on the secretor status of the mother, which is determined by her genetically defined blood group characteristics. Industrially, these oligosaccharides are produced biotechnologically, for example through microbial fermentation, for use as functional ingredients in infant formula.

Application in Infant Nutrition

Since breastfed infants benefit from the HMOs in breast milk, there is considerable interest in supplementing infant formula with HMOs such as difucosyllactose compounds to better approximate the composition of breast milk. Studies show that supplementation of infant formula with HMOs promotes the growth of Bifidobacterium longum subsp. infantis, improves stool consistency, and may reduce infection rates. Regulatory bodies, including the European Food Safety Authority (EFSA) in the European Union, have evaluated and approved the use of certain HMO compounds in infant nutrition.

Safety and Tolerability

The difucosyllactose mixture is considered safe and well-tolerated. Since these compounds are natural components of breast milk, their physiological safety is fundamentally established. No relevant adverse effects have been observed in clinical studies. Allergic reactions are not known, as these are structures familiar to the immune system.

Scientific Evidence

Research into human milk oligosaccharides, including the difucosyllactose mixture, has grown substantially in recent years. Preclinical and clinical studies confirm prebiotic, immunomodulatory, and antimicrobial effects. Nevertheless, further long-term studies are needed to fully characterize all health benefits in humans and to define optimal dosages for infant formula.

References

Bode, L. (2012). Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology, 22(9), 1147–1162. PubMed PMID: 22513036.
European Food Safety Authority (EFSA). Scientific Opinion on the safety of human milk oligosaccharides as novel foods. EFSA Journal, 2019.
Zivkovic, A. M., German, J. B., Lebrilla, C. B., & Mills, D. A. (2011). Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proceedings of the National Academy of Sciences, 108(Suppl 1), 4653–4658.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.